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Background: Limited research exists examining the impact of nutrition on golfing performance. This study’s
purpose was to determine the impact of daily supplementation with an over-the-counter dietary supplement on
golf performance.
Methods: Healthy men (30.3 ± 6.9 y, 183.1 ± 5.6 cm, 86.7 ± 11.9 kg), with a 5–15 handicap were assigned in a
double-blind, placebo-controlled manner to ingest for 30 days either a placebo (PLA, n = 13) or a dietary
supplement containing creatine monohydrate, coffea arabica fruit extract, calcium fructoborate and vitamin D
(Strong Drive™, SD, n = 14). Subjects ingested two daily doses for the first two weeks and one daily dose for the
remaining two weeks. Participants followed their normal dietary habits and did not change their physical activity
patterns. Two identical testing sessions in a pre/post fashion were completed consisting of a fasting blood
sample, anthropometric measurements, 1-RM bench press, upper body power and golf swing performance
using their driver and 7-iron. Data were analyzed using two-way mixed factorial ANOVAs and ANCOVA when
baseline differences were present. Statistical significance was established a priori at p ≤ 0.05.
Results: ANCOVA revealed significantly greater (post-test) best drive distance (p = 0.04) for SD (+5.0% [+13.6 yards],
ES = 0.75) as well as a tendency (p = 0.07) for average drive distance to increase (+8.4% [+19.6 yards], ES = 0.65), while
no such changes were found with PLA (−0.5% [−1.2 yards], ES = 0.04 and +1.3% [+2.8 yards], ES = 0.08, respectively).
Both groups experienced significant increases in body mass and 1-RM bench press (p < 0.001). No other significant
group × time interactions were found. For the SD group only, within-group analysis confirmed significant improvements
in set 1 average (+8.9%, p = 0.001) and peak velocity (+6.8%, p < =0.01). No changes were noted for reported adverse
events, pain inventories, quality of life or any measured blood parameter.
Conclusions: SD supplementation for 30 days significantly improved best drive distance more than placebo.
Supplementation was well tolerated and did not result in any clinically significant changes in markers of health or
adverse events/side effect profiles.
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The sport of golf requires an intricate mix of physical,
emotional and cognitive factors to achieve optimal per-
formance [1]. The swing itself is a complex pattern of
coordinated biomechanical movements that impact both
the accuracy and distance with which the ball is struck.
In its purest sense, the golf swing is a movement cen-
tered mostly upon the production of power; conse-
quently, swings are considered to be largely anaerobic
in nature [1].
As the popularity of golf rises, the development of er-
gogenic approaches have produced a seemingly endless
array of clubs and other pieces of equipment intended to
help improve performance. In light of the physical and
cognitive challenges brought forth by golf, nutritional
approaches may impact performance, but minimal effort,
to date, has been made in this area.
The lack of nutritional considerations within the sport
of golf is somewhat surprising. Currently, nutritional
guidelines center upon prudent management of fluid and
carbohydrate levels, but other demands found in golf
present the need for additional nutritional concerns. For
example, under certain environmental conditions the ex-
tended duration to complete a round of golf (~3 – 4 hours)
can promote dehydration, reduced energy levels and
mental fatigue [1]. When these factors are considered
collectively, it makes intuitive sense that a nutritional
formulation that can improve anaerobic performance
and increase a golfer’s focus and attention may impact
performance. In this respect, one of the only published
studies to examine the impact of a nutritional agent on
golfing performance utilized phosphatidylserine sup-
plementation to lower the stress hormone cortisol and
improve shot-making during simulated golf swings [2].
SuperDrive™ (Purity Products, Plainview, NY) is a com-
mercially available dietary supplement that combines
creatine monohydrate, coffee arabica fruit extract,
calcium fructoborate and vitamin D and is marketed to
the golfing community to aid in performance and re-
covery from musculoskeletal complications associated
with participation in golf [1].
Creatine monohydrate is one of the most popular and
effective dietary supplements due to its ability to improve
strength, power, lean mass and explosive performance.
Creatine supplementation protocols are well established
to significantly increase intramuscular levels of phospho-
creatine and total creatine which, in the vast majority of
studies, result in measureable improvements in a wide
variety of high-intensity activities [3-8]. However, to our
knowledge, no research is available that has examined the
impact of creatine supplementation on golfing perform-
ance. In light of the fact that the golf swing is an anaerobic
event [1], it is logical that creatine supplementation may
have the potential to improve golf swing power.Coffea arabica is a fruit extract (CoffeeBerry®) that is
derived from the same plant as traditional coffee, thus
making caffeine the primary active ingredient found
within the extract. For years, scientific research has sup-
ported the use of caffeine as an ergogenic aid, primarily
known for its positive impact on executive functions
such as focus, attention and concentration, stimulation
of fatty acid mobilization, improvements in endurance
performance [9], and various direct effects on muscle
function [10,11]. From a physical perspective, caffeine is
known to antagonize adenosine receptors, thereby inhibit-
ing the negative impact of adenosine on neurotransmission,
arousal, and pain perception [12] in addition to reducing
ratings of perceived exertion [13]. Beyond physical benefits,
caffeine can also operate to enhance a number of cognitive
aspects. Caffeine is commonly used and accepted for its
ability to promote wakefulness as well as enhance focus
and concentration, all attributes that would be of particular
benefit to a golfer, while also preventing both peripheral
and central manifestations of fatigue [10]. An excellent
review by Glade summarized available literature on
caffeine’s impact of cognitive functioning and reported
that caffeine in doses in modest amounts (30 – 50 mg)
are able to favorably impact mental energy, but typical
doses of 100 – 150 mg are needed to positively impact
assessments of cognitive functioning [10]. Similarly,
Einother and investigators expertly summarized the lit-
erature and concluded that caffeine favorably impacts
both simple and complex tasks through both attention
enhancement and optimized executive function [14].
A myriad of musculoskeletal problems can negatively
impact golfing performance and strategies to minimize
pain and joint discomfort while also promoting favorable
bone and muscle health are important concerns for
active golfers. The trace mineral boron is closely linked
to improved rates of calcium retention and bone health.
Although no recommended daily allowance for boron
has been established, doses ranging from 1–4 mg have
been shown to safely promote improvements in bone
density [15,16]. Recent technology has produced calcium
fructoborate (FruiteX-B®), a patented compound that
results in calcium being bound to boron, forming a nat-
ural chelation and effective stabilization of the available
boron. While relatively new, calcium fructoborate has
been shown to exert strong anti-inflammatory functions
[17] and pronounced antioxidant activity [18]. Interest-
ingly, the compound can favorably impact hormonal regu-
lation and vitamin D metabolism leading to its interest as
a pain and bone/joint health aid. Specifically, unpublished
research in mild and severe osteoporotic patients using
an open-label approach indicated that eight weeks of
supplementation with calcium fructoborate reduced pain
and stiffness during walking and climbing stairs and
improved joint mobility [19]. More recent published
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controlled supplementation approach on 116 osteopor-
otic patients and concluded that calcium fructoborate
supplementation improved inflammatory markers for
all groups [20].
Another ingredient that continues to get attention
regarding its ability to favorably impact bone health
[21] and healthy muscle metabolism [22-24] is vitamin
D. The average adult American diet contains only
150–300 IU of vitamin D per day while recommended
levels are 600–800 IU, despite multiple studies indicat-
ing that higher daily amounts may be optimal [21,25].
Currently, the Endocrine Society recommends 1,500 –
2,000 IU/day, with other reports recommending between
400 – 1,000 IU/day. To date, the impact of supple-
mentation with vitamin D (either in isolation or as part
of a multi-ingredient formula) on golf performance is
unknown.
The primary purpose of this preliminary, proof-of-
concept investigation was to examine the impact of
a nutritional formulation containing creatine, coffea
arabica fruit extract (CoffeeBerry®), calcium fructoborate
(FruiteX-B®) and vitamin D on functional indices of golf
swing performance, and upper-body strength/power. Sec-
ondary purposes were to assess changes in indices of qual-
ity of life, pain and standard blood-based markers of
clinical safety and health.
Methods
Overview of research design
This study was completed as a randomized, double-blind,
placebo-controlled trial. Over a 30 day period, eligible
study participants who first signed an IRB-approved in-
formed consent document were assigned in a randomized,
double-blind, placebo-controlled fashion to ingest either a
dietary supplement or a placebo. In an identical fashion,
two daily supplement (or placebo) doses were ingested
during the first two weeks and one daily dose was ingested
during the final two weeks for 30 days total. Prior to test-
ing, all study participants were instructed to refrain from
heavy exercise for 48 hours and observe a 12 hour fast. To
enhance reliability and minimize a learning effect, subjects
were familiarized to all experimental procedures prior to
testing. Participants then completed two identical testing
sessions consisting of a fasting blood sample, anthropo-
metric assessments, resting heart rate and blood pressure,
muscular strength and power assessments, golf swing
performance, and quality of life, pain and adverse event
questionnaires. To determine indications of clinical
safety, fasting blood samples were collected and ana-
lyzed for complete blood counts, clinical chemistry
panels and other indicators of health and safety along
with resting levels of heart and blood pressure. To as-
sess changes in strength and power and evaluate theimpact of supplementation, bench press 1-RM was deter-
mined along with bench press throw power, respectively.
In addition to these accepted laboratory methods of upper
body strength and power, functional performance was also
assessed using three-dimensional analysis of a series of
golf swings using participants’ 7-iron and driver. Finally
and as a general means to assess the impact of supplemen-
tation on potential changes in musculoskeletal health,
self-assessments of pain, quality of life and other adverse
outcomes were gleaned from all study participants.
Subjects
Twenty-seven healthy men (mean ± SD age, height, body
mass: 30.3 ± 6.9 y, 183.1 ± 5.6 cm, 86.7 ± 11.9 kg) with a
handicap index of 5–15 were recruited as participants in
this study. Prior to any research-related activity, all study
participants reviewed and signed an IRB approved in-
formed consent document (Integreview, Austin, TX,
Protocol #PUR-002, approval date: July 30, 2013). Dur-
ing their first laboratory visit, participants completed
medical history paperwork and were screened for eligi-
bility by a licensed physician. Inclusion criteria for this
study required study participants to be in good health
as determined by medical history review and baseline
blood chemistries, normotensive (systolic blood pres-
sure ≤ 140 mm Hg, diastolic blood pressure ≤ 90 mm
Hg and resting heart rate ≤ 90 beats per minute) and
have maintained a modest level of physical activity (de-
fined as an average of two workouts per week) for at
least one year. Participants were excluded if they had
any metabolic disorder including known electrolyte ab-
normalities, diabetes, thyroid disease, hypogonadism,
or a history of hepatic, renal, musculoskeletal, auto-
immune, or neurologic disease. Exclusion criteria also
included subjects with history of heart disease, hyper-
tension, psychiatric disorders, cancer, benign prostatic
hypertrophy, gastric ulcer, gastroesophegal reflux disease,
or any other medical disorder deemed unsuitable for in-
clusion in the study by the investigators. Participants who
reported a history of taking creatine or other dietary sup-
plements were only allowed entry if they had not taken or
had refrained from taking any dietary supplements con-
taining these ingredients for at least 30 days prior to initi-
ating the study (excluding a multi-vitamin/mineral) and
agreed to only use their assigned supplement throughout
the study protocol. Individuals who reported as regularly
consuming caffeine (<200 mg/day) were instructed to not
change their caffeine intake throughout the duration of
the protocol; participants who consumed >200 mg caf-
feine were excluded. Participants currently prescribed any
thyroid, antihyperlipidemic, hypoglycemic, antihyper-
tensive, anticoagulant, or androgenic medications, ni-
trates/nitrate derivatives, or phosphodiesterase (PDE)-5
inhibitors were also excluded. Subjects who had admitted
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growth factor (IGF)-1, or other hormone medication in-
cluding oral contraceptives during the previous 12 months
were also excluded, as were smokers and those with
orthopedic limitations or injuries.Figure 1 Supplement Facts for Strong Drive™.Procedures
Testing protocol
All study participants were first familiarized to all ex-
perimental procedures prior to completing their first
testing session. Prior to arriving for all testing sessions,
study participants were instructed to refrain from physic-
ally taxing exercise for 48 hours and to observe a 12 hour
fast. Upon arrival for the initial testing session, physical
activity and health history were determined using stan-
dardized questionnaires. Subjects then had their resting
heart rate and blood pressure determined using an auto-
mated sphygmomanometer, standing height determined
using a wall-mounted stadiometer, and body mass de-
termined using a calibrated scale (Seca Medical Scale,
Hanover, MD). On separate days thereafter, study par-
ticipants completed a 1-RM test on the bench press, an
upper-body power test (bench press throws) and an as-
sessment of their golf swing performance.Supplementation protocol
In a double-blind, placebo-controlled fashion, study par-
ticipants were instructed to ingest either a powdered
dietary supplement containing creatine, coffea arabica
fruit extract (CoffeeBerry®), calcium fructoborate (Frui-
teX-B®) and vitamin D (Strong Drive™, SD, n = 14) or an
isocaloric placebo (PLA, n = 13). A representative Sup-
plement Facts label of the investigational product is
shown in Figure 1. Irrespective of group assignment, all
study participants were instructed to take each serving
of their assigned supplement with eight ounces of cold
water. For the first two weeks of the study, one serving
was consumed twice per day (with breakfast and lunch).
During the final two weeks of the study, study participants
consumed only one serving per day of their assigned sup-
plement (with breakfast). This protocol was employed to
match manufacturer guidelines; the protocol also corre-
sponded with previous creatine supplementation literature
showing effective increases in intramuscular creatine and
phosphocreatine levels [3,6]. To ensure complete blinding,
all study supplements were in powder form of similar
color, texture and flavor while also being packaged in
coded generic containers. Compliance to the supplemen-
tation protocol was monitored by having study partici-
pants complete a supplementation log. In addition, study
participants were required to return their empty supple-
ment containers and were reminded of details associated
with the study protocols with weekly text messages and/oremails. Participants were instructed to refrain from using
other supplemental courses of caffeine or creatine.
Blood collection and analysis
Whole blood and serum samples were collected using
standard phlebotomy techniques on day 0 and day 30 of
the study protocol. Whole blood samples were collected
into K2-EDTA treated vacutainer tubes and upon collec-
tion were slowly inverted ten consecutive times prior to
immediate refrigeration. Serum samples were collected
in non-treated tubes and allowed to clot for 30 minutes
at room temperature prior to being centrifuged (Horizon
mini E Centrifuge, Drucker Diagnostics, Port Matilda,
PA) for 15 minutes at 3200 rpm. Serum was extracted
from all samples and aliquots were pipetted into cryovial
storage tubes. All blood samples were analyzed for
clinical chemistry analysis (plasma glucose, blood urea
nitrogen [BUN], creatinine, aspartate aminotransaminase
[AST], alanine aminotransaminase [ALT], creatine kinase,
lactate dehydrogenase, total bilirubin, alkaline phosphatase
[ALP], triacylglycerol [TG], total cholesterol [TC], LDL,
HDL, uric acid, sodium, potassium, total protein, albumin,
globulin, iron, complete blood cells, and platelet count)
using automated clinical chemistry analyzers (LabCorp,
Dublin, OH branch). All samples from the same day were
batch analyzed with test-retest reliabilities commonly
reported using internal quality control data from clinical
laboratories and associated automated analyzers within
a range of 3 – 5% [26].
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On day 0 and day 30, maximal upper body muscle
strength was estimated by 1-RM bench press testing
using protocols adapted from the National Strength and
Conditioning Association [27]. Only upper-body strength
was assessed in this study due to previous experience in
our lab and others indicating greater reliability of upper-
body vs. lower-body testing [28]. It is recognized that the
bench press exercise acts primarily in the sagittal plane
whereby the golf swing occurs through multiple planes
at a wide range of accelerations and decelerations. In
this respect, Marta and colleagues published a review
of EMG studies involving the golf swing and they re-
ported that the pectoralis muscle group experienced a
great deal of activity during the golf swing movement
[29]. Thus, our analytical approach in this styd was to
combine a standardized, well-accepted measure of
upper-body strength and power (1RM bench press and
bench throws) along with a three-dimensional analysis
of golf swing performance (described below) to assess
the potential impact of nutritional supplementation.
After a general warm-up of three to five minutes of
light activity consisting of upper body ergometry and
static stretching of the involved musculature, the subject
performed a warm-up set of ten repetitions with only the
bar, followed by eight repetitions at approximately 50% of
their estimated 1-RM, followed by one set of three repeti-
tions at 70% of their perceived 1-RM. Thereafter, study
participants performed single repetition lifts at progres-
sively increasing loads until 1-RM was determined. No
more than five maximal attempts were completed in one
testing session.
Upper body power production (average power [AP],
average velocity [AV], peak power [PP], peak velocity
[PV]) was assessed using the bench press exercise using
a Tendo unit interfaced to a standard Smith machine
rack. Previous studies have successfully incorporated the
use of a Tendo into their study design [30] and Stock
and colleagues [31] recently published data to indicate it
is a reliable means of assessment. The unit consists of a
position transducer that measures the rate of linear dis-
placement providing velocity and acceleration in addition
to power production. After 1RM determination, subjects
rested for five minutes and completed three sets of three
explosive repetitions (i.e. bench throws) with a load equal
to 40% of their actual 1-RM on the bench press. Interset
rest periods were strictly standardized at 90 seconds each.
The reliability of our procedures using these procedures is
similar to that previously reported [28,31].
Golf swing performance
On day 1 and day 30, golf swing performance was mea-
sured using a three-dimensional (3-D) swing analysis
system (TRACKMAN PRO, Brighton, MI) by a NCAADivision I golf coach. Study participants completed a
series of 10 successive swings using their 7-iron and
driver. Although a wide variety of data is captured with
this system (e.g. club delivery, ball launch, flight data)
for the purpose of this study we chose to focus on peak
and average club head speed, ball speed, as well as average
and best distance for each club. Reliability was determined
by having five representative participants complete five
swings using both the 7-iron and driver clubs. Intraclass
correlation coefficient and standard error of measurement
using the 7-iron were calculated for ball speed (ICC3,1:
0.934, SEM: 10.99 miles/hour), club speed (ICC3,1: 0.991,
SEM: 2.42 miles/hour) and total distance (ICC3,1: 0.862,
SEM: 41.74 yards). Identical measurements were made
using the driver for ball speed (ICC3,1: 0.975, SEM: 3.26
miles/hour) , club speed (ICC3,1: 0.990, SEM: 2.28 miles/
hour) and total distance (ICC3,1: 0.967, SEM: 8.46 yards).
All calculations and assumptions were made according to
Weir 2005 [32].
Qualitative assessments
Study participants were asked to maintain their normal
patterns of exercise and habitual physical activity. Assess-
ment of physical activity was completed on day 0, day 1
and day 30 using the Yale Physical Activity Survey prior to
the study protocol and again on the last day of testing
[33]. The Brief Pain Inventory and Quality of Life (SF-12,
version 2) were also administered on day 1 and day 30.
Dietary intake
No dietary restrictions or prescriptions were made as part
of this study protocol. Subjects recorded their dietary in-
take over a three day period (two week days, one weekend
day) according to instructions given by a research dietitian
on day 0 and day 30. Each subject’s baseline diet was ana-
lyzed by NutriBase IX software (CyberSoft, Inc., Phoenix,
AZ) to determine average energy and macronutrient con-
tent as well as distribution. Additional three-day dietary
records were collected and analyzed in an identical fash-
ion at the end of the supplementation protocol (day 30).
Twenty-four hours prior to post-testing on day 30, study
participants duplicated their dietary intake using diet re-
cords from day 0.
Statistical analyses
Data were analyzed using a two-way mixed factorial
ANOVA (treatment [PLA vs. SD] x time [pre vs. post])
with repeated measures on the time factor. ANCOVA
was utilized when baseline differences were present
using respective baseline scores as the covariate. Within-
group main effects over time were fully decomposed
using paired samples t-tests. Within-group effect sizes
(ES) were also calculated (post mean – pre mean/pooled
SD) for all variables and are reported in table format.
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Wilk statistics and visual inspection of standardized skew-
ness and kurtosis scores. When the sphericity assumption
was not met, the Huynh-Feldt correction was applied.
Any non-normally distributed data were log-transformed
prior to analysis. A p-value of less than or equal to 0.05
was used for determination of statistical significance.
Trends were identified as p-values between 0.051 and
0.10. All statistical analyses were completed using SPSS
software, version 21 (Cary, NC).
Results
Of the 45 people screened for this study, 30 met inclu-
sion criteria and were randomized to the study protocol.
Reasons for excluding participants included not achiev-
ing an adequate golf handicap score, taking medications
for blood pressure and not wanting to cease current sup-
plement use. Of the 30 people randomized into the
protocol, three participants were dropped because one
did not arrive for post-testing while two others failed to
show for their final golf swing performance test. Thus,
27 people completed the study. Descriptive characteris-
tics and baseline demographics are found in Table 1. No
significant differences (p > 0.05) were found at baseline
between groups for age, height, body mass, systolic
blood pressure, or diastolic blood pressure. Resting heart
rate values at baseline tended to be greater in the
PLA group (PLA: 67.5 ± 8.4 vs. SD: 61.4 ± 7.4 beats/
min, p = 0.052). In response to the intervention, no
significant group × time interaction (p > 0.05) effects
were revealed for body mass, systolic blood pressure,
diastolic blood pressure or resting heart rate.
Data from maximal strength and power assessments
are found in Table 2. Significant baseline differences
(p < 0.05) were found for maximal strength and peak
power production during all sets of the bench throws.
As a result, ANCOVA was used to determine statistical
differences for these variables during post-testing. Both
the PLA and SD groups experienced similar significant
increases in body mass (data not shown) and 1RM
bench press across time (p < 0.001 in both groups) withTable 1 Baseline anthropometric and hemodynamic characte
PLA (n = 13)
Age (years) 30.1 ± 7.9
Height (cm) 182.1 ± 5.4
Body mass (kg) 85.4 ± 9.0
Systolic BP (mm Hg) 133.3 ± 15.0
Diastolic BP (mm Hg) 81.5 ± 6.5
Resting HR (beats/min) 67.5 ± 8.4
1RM (kg) 85.1 ± 20.9
Values are mean ± SD. *Significant difference between groups via t-test, p < 0.05.but no between-group differences were present via
ANCOVA (p = 0.86). Using ANCOVA, no between group
differences (p > 0.05) were found for peak power produc-
tion during all sets that were completed (Table 2). Using
2x2 mixed factorial ANOVA, no significant group × time
interaction were found for peak velocity during set 2 and
set 3 while the peak velocity tended (p = 0.07) to change
for set 1 peak velocity (Table 2). Additionally, the SD
group experienced a significant within-group increase
(delta: 0.079 ± 0.089 miles/hour, p = 0.005; ES = 0.62) in
peak velocity during the 1st set of bench throws. In con-
trast, within-group changes in the PLA group for peak
velocity during set 1 of bench throws were not significant
(delta: 0.015 ± 0.086, p = 0.55; ES = 0.11).
Golf performance data are shown in Table 3. Using
2×2 mixed factorial ANOVA, no significant (p > 0.05)
group × time interaction effect was found for best 7-iron
club speed, best 7-iron ball speed and best 7-iron distance.
There was a significant difference at baseline (p < 0.05) in
best driver distance, best driver club speed, and best driver
ball speed, thus ANCOVA was used to compare post-test
values for these variables. No between-group differences
were noted for best driver club speed and best driver ball
speed, but a significant difference was found for best
driver distance (Table 3 and Figure 2) and there was a
tendency for average driver distance to be different
(PLA: 2.7 ± 25.2 vs. SD: 13.6 ± 24.5 yards, p = 0.07). In
the SD group, a trend (delta: 13.6 ± 29.0 yards, p = 0.10,
ES = 0.75) was identified for best drive distance. No
within-group changes were seen in the PLA group for
any of the golf performance parameters with the excep-
tion of a tendency for an increase in best 7-iron distance
(+6.9 ± 13.2 yards, p = 0.08, ES = 0.31).
No significant group × time interaction effects were
revealed for the following blood variables (Table 4): red
blood cell count, hemoglobin, hematocrit, glucose, blood
urea nitrogen (BUN), creatinine, BUN: creatinine, so-
dium, potassium, chloride, carbon dioxide, calcium, total
protein, albumin, globulin, albumin: globulin, bilirubin,
alkaline phosphatase, alanine aminotransferase, aspartate
aminotransferase, total cholesterol, triglycerides, HDLristics of study participants
SD (n = 14) Between groups (p)
30.5 ± 6.0 0.876
184.0 ± 5.7 0.392
87.8 ± 14.4 0.601
129.6 ± 11.0 0.464
80.0 ± 6.9 0.556
61.4 ± 7.4 0.052
105.5 ± 25.0 0.031*
Table 2 Upper-body maximal strength and power characteristics
Intervention Comparison of change (p)
Pre Post Change Effect size (d) Within groups Group × Time
Bench press 1RM (kg)
PLA 85 ± 21 89 ± 22 3.8 ± 3.0 0.18 <0.01* 0.86§
SD 106 ± 25† 109 ± 25 3.7 ± 2.9 0.15 <0.01*
Bench Press Throws Peak Power Set 1 (watts)‡
PLA 396 ± 91 410 ± 105 14.5 ± 43.8 0.16 0.26 0.35§
SD 487 ± 124 517 ± 124 28.6 ± 26.7 0.23 <0.01*
Bench Press Throws Peak Velocity Set 1 (m/s)‡
PLA 1.20 ± 0.13 1.22 ± 0.12 0.015 ± 0.086 0.11 0.55 0.07
SD 1.17 ± 0.13 1.25 ± 0.11 0.079 ± 0.089 0.62 0.02*
Bench Press Throws Peak Power Set 2 (watts)‡
PLA 401 ± 86 422 ± 108 21.4 ± 44.7 0.25 0.11 0.36§
SD 504 ± 124 513 ± 129 8.7 ± 38.8 0.07 0.42
Bench Press Throws Peak Velocity Set 2 (m/s)‡
PLA 1.21 ± 0.10 1.24 ± 0.16 0.025 ± 0.132 0.26 0.52 0.86
SD 1.22 ± 0.15 1.24 ± 0.10 0.016 ± 0.096 0.11 0.53
Bench Press Throws Peak Power Set 3 (watts)‡
PLA 400 ± 95 416 ± 97 15.5 ± 36.8 0.16 0.15 0.75§
SD 515 ± 118 523 ± 126 8.5 ± 40.3 0.07 0.44
Bench Press Throws Peak Velocity Set 3 (m/s)‡
PLA 1.21 ± 0.10 1.24 ± 0.12 0.032 ± .109 0.31 0.31 0.61
SD 1.25 ± 0.14 1.27 ± 0.09 0.012 ± 0.093 0.08 0.63
Values are mean ± SD. ‡= 3 sets × 3 reps of bench press throws @ 40% 1RM. § = Group differences assessed using ANCOVA with respective baseline scores as the
covariate due to significant difference between groups at baseline. *= Significant within group change.
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D (25-hydroxy D) and C-reactive protein. Only a small
number of blood variables experienced changes or
seemed to exhibit within-group changes over time. In all
situations, the magnitude of change was within clinically
accepted normative ranges for these variables. Specific-
ally, in the SD group significant changes (p < 0.05) were
noted in diastolic blood pressure, carbon dioxide, and
total cholesterol while in the PLA group significant
changes were noted in sodium, potassium, and glucose.
Both groups experienced significant changes in total
protein, globulin, and albumin: globulin ratio. No signifi-
cant group × time interaction effects were reported for
any of the pain indices, physical activity or enjoyment
scales (Table 5, p > 0.05).
Discussion
Golf is a unique sport that requires a challenging com-
bination of physical, mental and emotional attributes.
Nutritional formulations developed to enhance these
attributes are lacking, but multiple ingredients are avail-
able that have been examined scientifically which may
improve golfing performance. The primary findings fromthe present study were that, over a 4-week period of
supplementation, a blend of ingredients found in SD
(e.g. creatine monohydrate, coffea arabica fruit extract
[CoffeeBerry®], calcium fructoborate [FruiteX-B®], and
vitamin D) significantly increased best drive distance
and tended to improve average driver distance (p = 0.07)
more so than the placebo group. In addition, both groups
experienced significant improvements in bench press
strength while the SD also experienced significant improve-
ments in peak power and peak velocity production after the
first set of bench press throws while no such changes were
observed in the placebo group. Supplementation was well
tolerated and no safety concerns/side effects were noted.
Although this study was not designed to determine the
mechanisms underpinning any observed changes with
SD supplementation, one or more of the ingredients in
the formula were likely responsible for the observed
changes. For example, a number of previous investiga-
tions using creatine monohydrate at the dosage provided
in this study (10 grams/day × first two weeks, 5 grams/
day × last two weeks) have routinely reported improve-
ments in strength, upper-body performance, power and
overall exercise capacity [3,7]. Thus, even though we did
Table 3 Golf performance using repeated measures ANOVA
Intervention Comparison of change (p)
Pre Post Change Effect size (d) Within groups Group × Time
Best 7 Iron Club Speed (miles/hour)
PLA 86.7 ± 8.9 88.0 ± 4.6 1.39 ± 4.9 0.15 0.32 0.50
SD 92.1 ± 4.8 92.5 ± 5.2 0.44 ± 1.7 0.09 0.34
Best 7 Iron Ball Speed (miles/hour)
PLA 113.8 ± 12.9 115.4 ± 8.8 1.51 ± 7.5 0.11 0.79 0.44
SD 120.8 ± 6.3 120.5 ± 6.9 −0.25 ± 3.9 0.04 0.80
Best Distance 7 Iron (yards)
PLA 162 ± 24 169 ± 21 6.9 ± 13 0.31 0.08 0.93
SD 174 ± 15 181 ± 13 7.4 ± 18 0.53 0.14
Best Driver Club Speed (miles/hour)
PLA 104.5 ± 9.3 104.9 ± 6.5 0.45 ± 4.6 0.05 0.73 0.46§
SD 110.4 ± 5.1 110.1 ± 5.7 −0.31 ± 3.6 0.06 0.76
Best Driver Ball Speed (miles/hour)
PLA 147.5 ± 13.8 148.6 ± 9.5 1.1 ± 7.5 0.09 0.61 0.17§
SD 158.9 ± 6.6 159.1 ± 7.9 0.19 ± 7.6 0.03 0.93
Best Driver Distance (yards)
PLA 260.0 ± 30.4 258.8 ± 29.6 −1.2 ± 18.6 0.04 0.82 0.04§
SD 269.9 ± 18.5 283.5 ± 23.1 13.6 ± 29.0 0.75 0.10
Values are mean ± SD. §= Group differences assessed using ANCOVA with respective baseline scores as the covariate due to significant difference between groups
at baseline.
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observed non-significant improvements in upper-body
power and velocity primarily stemmed from the creatine
monohydrate contained in SD. Future studies should
utilize three groups to confirm this hypothesis (i.e. pla-



























Figure 2 Best distance using driver for placebo = PLA (black bars) and
using ANCOVA (p = 0.04) with respective baseline scores as the covariate dAnother potential candidate for performance enhance-
ment in the SD formula is caffeine. As a dietary supple-
ment, caffeine has successfully been used for years at doses
of 3–6 mg/kg of body mass to improve both cognitive and
physical aspects of exercise performance [10,11]. In the
present study, no assessments of focus or concentrationtsoP
§ 
Strong Drive = SD (white bars). § = Significant group differences
ue to significant differences between groups at baseline.
Table 4 Hemodynamic, whole blood and clinical chemistry markers of health and safety
Intervention Comparison of change (p)
Pre Post Change Effect Size (d) Within Groups Group x Time
Resting Heart Rate (beats/min)
PLA 67.5 ± 8.4 66.8 ± 7.2 −0.7 ± 6.3 0.09 0.70 0.81
SD 61.4 ± 7.4 60.1 ± 6.2 −1.3 ± 6.2 0.19 0.45
Systolic Blood Pressure (mm Hg)
PLA 133.3 ± 15.0 125.9 ± 12.3 −7.4 ± 13.2 0.54 0.07 0.76
SD 129.6 ± 11.0 123.7 ± 10.2 −5.9 ± 12.2 0.56 0.10
Diastolic Blood Pressure (mm Hg)
PLA 81.5 ± 6.5 79.5 ± 6.6 −1.9 ± 5.6 0.16 0.22 0.10
SD 80.0 ± 6.9 73.0 ± 9.6 −7.1 ± 9.1 0.85 0.01*
White Blood Cell Count (x106/UL)
PLA 5.6 ± 0.9 5.4 ± 1.4 −0.19 ± 1.4 0.13 0.62 0.55
SD 4.6 ± 1.4 4.7 ± 1.1 −0.14 ± 1.4 0.08 0.73
Red Blood Cell Count (x106/UL)
PLA 5.3 ± 0.4 5.2 ± 0.4 −0.06 ± 0.21 0.40 0.30 0.83
SD 5.0 ± 0.3 5.0 ± 0.3 −0.05 ± 0.09 0.00 0.07
Hemoglobin (grams/dL)
PLA 15.7 ± 1.0 15.5 ± 1.0 −0.24 ± 0.6 0.20 0.16 0.20
SD 14.6 ± 0.9 14.7 ± 0.7 −0.57 ± 0.6 0.12 0.72
Hematocrit (%) 0.96
PLA 46.0 ± 2.9 45.6 ± 2.9 −0.45 ± 1.9 0.14 0.42
SD 43.3 ± 1.7 42.8 ± 1.9 −0.42 ± 0.9 0.28 0.10
Glucose (mg/dL) 0.10
PLA 93.0 ± 5.7 87.1 ± 7.0 −5.8 ± 7.1 0.90 0.01*
SD 88.9 ± 8.2 90.6 ± 11.4 −1.9 ± 15.0 0.20 0.64
Blood Urea Nitrogen (mg/dL) 0.35
PLA 15.4 ± 3.7 15.1 ± 4.3 −0.31 ± 2.4 0.07 0.65
SD 18.7 ± 6.3 19.2 ± 6.4 - 0.5 ± 2.0 0.08 0.37
Creatinine (mg/dL) 0.28
PLA 1.01 ± 0.17 1.02 ± 0.16 0.00 ± 0.09 0.00 0.76
SD 1.08 ± 0.11 1.13 ± 0.12 0.05 ± 0.11 0.00 0.11
BUN:Creatinine 0.57
PLA 15.1 ± 2.6 14.7 ± 3.9 −0.38 ± 2.1 0.12 0.52
SD 17.2 ± 5.0 17.3 ± 6.1 −0.07 ± 2.1 0.02 0.90
Sodium (mEq/L) 0.47
PLA 139.5 ± 1.6 140.4 ± 1.2 0.92 ± 1.4 0.64 0.04*
SD 139.7 ± 1.5 140.1 ± 1.1 0.43 ± 2.0 0.30 0.44
Potassium (mEq/L) 0.14
PLA 4.2 ± 0.26 4.5 ± 0.19 0.31 ± 0.36 1.18 0.01*
SD 4.3 ± 0.32 4.4 ± 0.34 0.11 ± 0.33 0.39 0.25
Chloride (mEq/L) 0.32
PLA 102.3 ± 2.1 102.0 ± 1.1 −0.31 ± 1.7 0.18 0.52
SD 102.3 ± 1.9 101.4 ± 1.7 −0.93 ± 1.5 0.50 0.04*
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Carbon Dioxide (mmol/L) 0.11
PLA 24.1 ± 1.4 24.5 ± 1.8 0.46 ± 1.8 0.25 0.36
SD 24.8 ± 2.2 26.4 ± 2.0 1.57 ± 1.7 0.76 0.005*
Calcium (mg/dL) 0.31
PLA 9.63 ± 0.34 9.68 ± 0.39 −0.05 ± 0.33 0.28 0.62
SD 9.49 ± 0.31 9.39 ± 0.22 −0.1 ± 0.40 0.39 0.37
Total Protein (g/L) 0.69
PLA 7.39 ± 0.34 7.08 ± 0.39 −0.31 ± 0.36 0.85 0.01*
SD 6.96 ± 0.28 6.70 ± 0.28 −0.26 ± 0.30 1.00 0.007*
Albumin (g/dL) 0.72
PLA 4.64 ± 0.30 4.65 ± 0.27 −0.01 ± 0.25 0.33 0.91
SD 4.60 ± 0.16 4.58 ± 0.14 −0.02 ± 0.15 0.00 0.61
Globulin (g/dL) 0.27
PLA 2.75 ± 0.23 2.43 ± 0.26 −0.32 ± 1.7 1.18 <0.001*
SD 2.36 ± 0.26 2.12 ± 0.23 −0.24 ± 0.19 1.18 <0.001*
Albumin: Globulin 0.62
PLA 1.70 ± 0.20 1.93 ± 0.24 0.23 ± 0.15 1.00 <0.001*
SD 1.99 ± 0.25 2.19 ± 0.26 0.20 ± 0.17 0.67 <0.001*
Bilirubin (mg/dL) 0.94
PLA 0.62 ± 0.25 0.60 ± 0.27 −0.02 ± 0.13 0.00 0.67
SD 0.65 ± 0.21 0.63 ± 0.31 −0.02 ± 0.25 0.39 0.75
Alkaline Phosphatase (U/L) 0.89
PLA 74.0 ± 22.6 74.2 ± 24.4 0.15 ± 12.2 0.01 0.96
SD 67.1 ± 13.8 66.8 ± 14.8 –0.4 ± 5.3 0.02 0.81
Aspartate Aminotransferase, AST (U/L) 0.59
PLA 25.9 ± 15.3 24.7 ± 13.6 −1.23 ± 6.23 0.08 0.49
SD 28.0 ± 10.2 27.8 ± 9.5 −0.21 ± 2.83 0.02 0.78
Alanine Aminotransferase, ALT (U/L) 0.66
PLA 31.2 ± 16.9 29.0 ± 16.3 −2.15 ± 7.6 0.13 0.33
SD 27.3 ± 11.7 23.9 ± 8.8 −3.4 ± 6.5 0.33 0.07
Total Cholesterol (mg/dL) 0.55
PLA 186.2 ± 48.0 182.2 ± 46.2 −3.9 ± 26.8 0.08 0.61
SD 166.3 ± 40.6 157.3 ± 35.9 −9.0 ± 15.9 0.23 0.053*
Triglycerides (mg/dL) 0.34
PLA 116.0 ± 51.7 115.8 ± 78.7 −0.23 ± 55.3 0.00 0.99
SD 92.0 ± 84.3 71.8 ± 36.6 −20.2 ± 50.6 0.31 0.16
HDL Cholesterol (mg/dL) 0.36
PLA 47.5 ± 9.4 47.2 ± 11.6 −0.31 ± 6.0 0.03 0.86
SD 53.1 ± 12.9 50.9 ± 10.5 −2.21 ± 4.6 0.19 0.10
VLDL Cholesterol (mg/dL) 0.33
PLA 23.2 ± 10.3 23.2 ± 15.7 0.00 ± 11.2 0.00 1.00
SD 18.4 ± 17.0 14.3 ± 7.3 −4.14 ± 10.2 0.31 0.15
LDL Cholesterol (mg/dL) 0.90
PLA 115.5 ± 41.6 111.9 ± 40.5 −3.62 ± 23.6 0.09 0.59
SD 94.7 ± 31.4 92.1 ± 32.7 −2.64 ± 14.4 0.08 0.51
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Table 4 Hemodynamic, whole blood and clinical chemistry markers of health and safety (Continued)
Vitamin D (as 25(OH)D, ng/mL) 0.46
PLA 21.5 ± 5.2 23.3 ± 5.0 1.78 ± 3.94 0.35 0.13
SD 35.1 ± 29.0 40.9 ± 45.4 3.95 ± 19.0 0.15 0.27
C-Reactive Protein (mg/L) 0.64
PLA 1.41 ± 0.90 1.19 ± 0.65 −0.22 ± 0.6 0.25 0.19
SD 1.46 ± 1.57 1.03 ± 1.11 −0.43 ± 1.5 0.36 0.29
Values are mean ± SD. *= Significant within group change via t-test.
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tion because of the relatively low dose of caffeine in the test
product (i.e. 50 mg or ~ 0.6 mg/kg body mass for these
subjects). In addition, the last dose of SD (or placebo) was
taken 24-hours prior to day 30 testing. Thus, we consider
it unlikely that the caffeine contained in the coffea arabica
fruit extract (CoffeeBerry®) of SD played a major role in the
results. It is worth mentioning we cannot completely dis-
count the potential effects that other unique ingredients
in CoffeeBerry® (e.g., various chlorogenic acids and plant
phenolics), may have had on these results.
Finally, data surrounding boron and vitamin D con-
tinue to lend support towards these nutrients and their
ability to mitigate pain [20] as well as improve bone [21]
and muscle health [23]. Findings from the present study
did not reveal improved outcomes associated with self-
reported pain, fatigue or weakness levels as assessed be-
fore and after the four week supplementation period.
We speculate that the primary reason for these findings
was associated with the existing joint and bone health of
our study participants. For example, our study partici-
pants were otherwise healthy, middle-aged men who
golfed on a regular basis and as a result were maintain-
ing a basic level of physical activity. When compared to
the study participants in other published trials showing
improvements in self-reported pain [19-21,24], partici-
pants from the present study were younger, healthier and
had minimal baseline levels of pain. The lack of change
found in serum levels of 25-hydroxy vitamin D as a result
of supplementation was not entirely unexpected. Given
the moderate dose (1,000 IU/day), the time of year the
study was conducted (late Fall), and general latitude of the
study location (Kent, OH= 41.15° N), it is our contention
that the majority of supplemented vitamin D was quickly
absorbed by peripheral tissues.
From an adverse event and/or clinical safety perspective,
the SD supplement was well tolerated with no significant
group × time interactive changes in any of the measured
clinical markers (Tables 4 and 5). A few variables did
experience significant within-group changes (e.g., diastolic
blood pressure, glucose, sodium, potassium, carbon diox-
ide, albumin: globulin ratio, total protein and globulin,
etc.), but in all such circumstances, both groups changes
remained within clinical accepted normative values.The strengths of the present study are that it was a
double-blind, placebo-controlled investigation using a
“free-living” approach. Thus, the findings are applicable
to many consumers who golf but do not follow a rigid
diet or exercise program. To date, extremely limited re-
search is available exploring the potential impact of vari-
ous nutritional agents on golf performance, with one of
the only published accounts reporting an improvement
in stress hormone levels and shot-making after phospha-
tidylserine supplementation [2]. The disadvantages of
the present study primarily revolve around the pilot na-
ture of the investigation and the lack of female subjects.
The authors recognize that the relatively small number
of subjects and short supplementation period (4 weeks)
likely hindered the ability to uncover significant effects
in some outcome measures, particularly since the partic-
ipants were relatively young and healthy and were not
required to follow a particular exercise training program
or dietary regimen. It is also important to discuss other
considerations related to our data and findings. For
example, the positive outcome surrounding best drive
distance is likely impacted by a number of other factors
that we weren’t able to be measured in our study design
including, but not limited to: club head acceleration at
the point of impact with the ball, club head deceleration
through the zone of impact, rotational power, improved
accuracy of club head placement relative the ball, club
face angle at ball strike, and musculoskeletal range of
motion. Two additional factors are upper-body strength
and power that were measured in the present study by
determining bench press 1RM and sagittal plane power
development during bench press throws. The authors
recognize that performance of the bench press exercise
may be viewed by some as having very little carryover to
golf swing performance, but these parameters were
chosen due to their high reliability of measurement and
as being valid and commonly used measures of maximal
strength and power in the sports science literature.
Additionally, it is important to highlight that Marta and
colleagues indicate that the pectoralis major, deltoid,
and latissimus dosi are the most active muscle groups
during the golf swing movement, particularly during the
acceleration phase [29]. A three-dimensional analysis of
golf swing performance using two common clubs was
Table 5 Pain and quality of life data
Intervention Comparison of change (p)
Pre Post Change Effect size (d) Within groups Group × Time
Worst Pain
PLA 1.62 ± 2.60 1.38 ± 2.14 −0.23 ± 1.09 0.08 0.46 0.52
SD 0.79 ± 1.31 0.93 ± 1.33 0.14 ± 1.79 0.08 0.77
Least Pain
PLA 0.31 ± 0.63 0.31 ± 0.85 0.00 ± 0.58 0.00 1.00 0.50
SD 0.36 ± 0.74 0.14 ± 0.53 −0.21 ± 0.97 0.49 0.43
Average Pain
PLA 1.38 ± 1,89 1.15 ± 1.52 −0.23 ± 0.83 0.12 0.34 0.97
SD 0.79 ± 1.12 0.57 ± 1.09 −0.21 ± 1.53 0.18 0.61
Pain Level Now
PLA 0.69 ± 1.44 0.69 ± 1.32 0.00 ± 1.68 0.00 1.00 0.48
SD 0.43 ± 0.94 0.07 ± 0.27 −0.36 ± 0.74 0.45 0.10
Relief
PLA 13.8 ± 34.0 6.2 ± 22.2 −7.7 ± 27.7 0.26 0.34 0.53
SD 16.4 ± 33.9 18.6 ± 37.0 −2.1 ± 49.0 0.06 0.87
Current Activity 0.88
PLA 0.54 ± 1.13 0.31 ± 0.85 −0.23 ± 1.4 0.20 0.55
SD 0.50 ± 1.34 0.36 ± 0.74 −0.14 ± 1.7 0.10 0.75
Current Mood 0.45
PLA 0.31 ± 0.75 0.15 ± 0.38 −0.15 ± 0.69 0.16 0.44
SD 0.14 ± 0.53 0.21 ± 0.60 −0.07 ± 0.83 0.18 0.75
Walking 0.08
PLA 0.38 ± 1.12 0.85 ± 1.81 −0.46 ± 0.97 0.27 0.11
SD 0.21 ± 0.43 0.14 ± 0.53 −0.07 ± 0.47 0.22 0.58
Normal Work 0.67
PLA 0.31 ± 0.63 0.23 ± 0.60 −0.07 ± 0.76 0.17 0.72
SD 0.43 ± 0.94 0.21 ± 0.58 −0.21 ± 0.89 0.26 0.39
Sleep Quality 0.48
PLA 0.46 ± 1.1 0.45 ± 1.1 0.00 ± 1.0 0.00 1.00
SD 0.43 ± 1.1 0.14 ± 0.4 −0.29 ± 1.1 0.36 0.34
Yale P1 0.26
PLA 5471 ± 4118 5954 ± 4705 - 483 ± 2436 0.11 0.49
SD 6376 ± 6967 5175 ± 2238 −1200 ± 4755 0.22 0.36
Yale P2 0.77
PLA 85.5 ± 34.3 64.3 ± 26.1 −21.2 ± 45.6 0.70 0.12
SD 114.9 ± 57.6 86.5 ± 52.5 −28.4 ± 76.8 0.52 0.19
PCS 0.35
PLA 52.6 ± 7.1 56.0 ± 2.8 3.4 ± 5.7 0.63 0.05
SD 53.9 ± 4.3 55.5 ± 2.7 1.6 ± 4.0 0.45 0.17
MCS 0.59
PLA 55.5 ± 4.2 53.6 ± 6.5 −1.87 ± 6.58 0.35 0.33
SD 56.1 ± 5.1 55.3 ± 3.5 −0.82 ± 2.85 0.18 0.30
Values are mean ± SD. No significant changes between or within groups were noted.
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ance. While much more practical, this measurement
method only reports on final performance and thus does
not allow for a clearer understanding of what aspects of
performance SD may have improved according to our
findings, particularly as they relate to best drive distance.
In this respect, it is important for the reader to understand
other factors may have impacted our observed outcomes
related to best driver distance.
Conclusions
This preliminary investigation yielded significantly greater
improvements in best drive distance (~13.6 yards) and a
tendency for average driver distance to improve in healthy
male golfers consuming SD for four weeks. Careful inter-
pretation of these data is encouraged due to their prelim-
inary nature and need to be followed-up with a larger and
longer investigation.
Competing interests
The authors declare that they have no competing or financial interests
concerning the outcome of this investigation. The sponsor of this study,
Purity Products (Plainview, NY) provided an independent research grant and
donated the study product (SD) and placebo, but had no role in the
collection, analyses, or interpretation of the data.
Authors’ contributions
AWK provided medical oversight, subject screening, subject recruitment and
assisted with data collection and manuscript preparation. TNZ and HLL
designed the study, secured funding for project, assisted with data analysis
and manuscript preparation. JES and SMH carried out subject recruitment,
data collection, coordination of the study and compliance. RLA coordinated
and assisted with all golf simulations and performance assessments. CMK
assisted with data analysis and prepared the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
The authors would like to thank the subjects who participated in the study
and the sponsor (Purity Products). The presentation of results of this study
does not constitute endorsement by the any of the investigators, the
universities they represent, The Center for Applied Health Sciences, or the
journal in which it is published.
Author details
1The Center for Applied Health Sciences, 4302 Allen Road, Ste 120, Stow, OH
44224, USA. 2Strength and Conditioning, Athletics Department, Kent State
University, Kent, OH 44240, USA. 3School of Sport, Recreation and Exercise
Sciences, Lindenwood University, St. Charles, MO 63301, USA.
Received: 25 July 2014 Accepted: 18 December 2014
References
1. Smith MF. The role of physiology in the development of golf performance.
Sports Med. 2010;40(8):635–55.
2. Jager R, Purpura M, Geiss KR, Weiss M, Baumeister J, Amatulli F, Schroder L,
Herwegen H. The effect of phosphatidylserine on golf performance. J Int
Soc Sports Nutr. 2007;4(1):23.
3. Buford TW, Kreider RB, Stout JR, Greenwood M, Campbell B, Spano M,
Ziegenfuss T, Lopez H, Landis J, Antonio J. International Society of Sports
Nutrition position stand: creatine supplementation and exercise. J Int Soc
Sports Nutr. 2007;4:6.
4. Greenhaff PL. Muscle creatine loading in humans: Procedures and
functional and metabolic effects. In: 6th International Conference on
Guanidino Compounds in Biology and Medicine: 2001. Cincinnati, OH; 2001.5. Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine
supplementation on skeletal muscle phosphocreatine resynthesis. Am J
Physiol. 1994;266(5 Pt 1):E725–30.
6. Hultman E, Soderlund K, Timmons JA, Cederblad G, Greenhaff PL. Muscle
creatine loading in men. J Appl Physiol. 1996;81(1):232–7.
7. Kreider RB. Effects of creatine supplementation on performance and
training adaptations. Mol Cell Biochem. 2003;244(1–2):89–94.
8. Kreider RB, Ferreira M, Wilson M, Grindstaff P, Plisk S, Reinardy J,
Cantler E, Almada AL. Effects of creatine supplementation on body
composition, strength, and sprint performance. Med Sci Sports Exerc.
1998;30(1):73–82.
9. Astorino TA, Roberson DW. Efficacy of acute caffeine ingestion for short-
term high-intensity exercise performance: a systematic review. J Strength
Cond Res. 2010;24(1):257–65.
10. Glade MJ. Caffeine-Not just a stimulant. Nutrition. 2010;26(10):932–8.
11. Goldstein ER, Ziegenfuss T, Kalman D, Kreider R, Campbell B, Wilborn C,
et al. International society of sports nutrition position stand: caffeine and
performance. J Int Soc Sports Nutr. 2010;7(1):5.
12. Davis JK, Green JM. Caffeine and anaerobic performance: ergogenic value
and mechanisms of action. Sports Med. 2009;39(10):813–32.
13. Doherty M, Smith PM. Effects of caffeine ingestion on rating of perceived
exertion during and after exercise: a meta-analysis. Scand J Med Sci Sports.
2005;15(2):69–78.
14. Einother SJ, Giesbrecht T. Caffeine as an attention enhancer: reviewing
existing assumptions. Psychopharmacology. 2013;225(2):251–74.
15. Armstrong TA, Spears JW, Crenshaw TD, Nielsen FH. Boron supplementation
of a semipurified diet for weanling pigs improves feed efficiency and bone
strength characteristics and alters plasma lipid metabolites. J Nutr.
2000;130(10):2575–81.
16. Hooshmand S, Chai SC, Saadat RL, Payton ME, Brummel-Smith K, Arjmandi
BH. Comparative effects of dried plum and dried apple on bone in
postmenopausal women. Br J Nutr. 2011;106(6):923–30.
17. Scorei RI, Rotaru P. Calcium fructoborate–potential anti-inflammatory agent.
Biol Trace Elem Res. 2011;143(3):1223–38.
18. Scorei R, Cimpoiasu VM, Iordachescu D. In vitro evaluation of the
antioxidant activity of calcium fructoborate. Biol Trace Elem Res.
2005;107(2):127–34.
19. Miljukovic ND, Miljkovic DA, Ercegan GM. Osteoarthritis and Calcium Fructo
Borate Supplementation: An Open-Label Pilot Study. Yugoslavia: University
of Novi Sad; 2002.
20. Scorei R, Mitrut P, Petrisor I, Scorei I. A double-blind, placebo-controlled pilot
study to evaluate the effect of calcium fructoborate on systemic inflammation
and dyslipidemia markers for middle-aged people with primary osteoarthritis.
Biol Trace Elem Res. 2011;144(1–3):253–63.
21. Price CT, Langford JR, Liporace FA. Essential Nutrients for Bone Health and a
Review of their Availability in the Average North American Diet. Open
Orthopaedics J. 2012;6:143–9.
22. Eglia L. Vitamin D and its role in skeletal muscle. Curr Opin Clin Nutr Metab
Care. 2009;12(6):628–33.
23. Hamilton B. Vitamin D and human skeletal muscle. Scand J Med Sci Sports.
2010;20(2):182–90.
24. Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents muscular
atrophy and reduces falls and hip fractures in women after stroke: a
randomized controlled trial. Cerebrovasc Dis. 2005;20(3):187–92.
25. Calvo MS, Whiting SJ, Barton CN. Vitamin D fortification in the United States
and Canada: current status and data needs. Am J Clin Nutr.
2004;80(6 Suppl):1710S–6.
26. Cuka S, Dvornik S, Drazenovic K, Mihic J. Evaluation of the Dade Behring
Dimension RxL clinical chemistry analyzer. Clin Lab. 2001;47(1–2):35–40.
27. Baechle TR, Earle RW. Essentials of Strength Training and Conditioning.
Champaign, IL: Human Kinetics; 2000.
28. Alemany JA, Pandorf CE, Montain SJ, Castellani JW, Tuckow AP, Nindl BC.
Reliability assessment of ballistic jump squats and bench throws. J Strength
Cond Res. 2005;19(1):33–8.
29. Marta S, Silva L, Castro MA, Pezarat-Correia P, Cabri J. Electromyography
variables during the golf swing: a literature review. J Electromyogr Kinesiol.
2012;22(6):803–13.
30. Hoffman JR, Ratamess NA, Kang J, Rashti SL, Faigenbaum AD. Effect of
betaine supplementation on power performance and fatigue. J Int Soc
Sports Nutr. 2009;6:7.
Ziegenfuss et al. Journal of the International Society of Sports Nutrition  (2015) 12:4 Page 14 of 1431. Stock MS, Beck TW, DeFreitas JM, Dillon MA. Test-retest reliability of barbell
velocity during the free-weight bench-press exercise. J Strength Cond Res.
2011;25(1):171–7.
32. Weir JP. Quantifying test-retest reliability using the intraclass correlation
coefficient and the SEM. J Strength Cond Res. 2005;19(1):231–40.
33. Kruskall LJ, Campbell WW, Evans WJ. The Yale Physical Activity Survey for
older adults: predictions in the energy expenditure due to physical activity.
J Am Diet Assoc. 2004;104(8):1251–7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
